BIO Announces Presenting Companies for 16th Annual BIO CEO & Investor Conference
WASHINGTON, D.C. (December 19, 2013) - The Biotechnology Industry Organization (BIO) today announced the preliminary list of presenting companies for the 16th Annual BIO CEO & Investor Conference to be held February 10-11, 2014 in New York City. Presenting companies are hand-selected for the event, and consist of a selection of mid- to large-cap established public as well as late-stage private companies from around the globe. These companies typically have a clinical stage program centered around therapeutics, molecular diagnostics or a platform technology, as well as an upcoming clinical, regulatory or corporate catalyst.
“2013 has been a banner year for the biotech sector. We have seen more than 40 biotech IPOs this year alone, 15 of which will be represented through company presentations,” said BIO president & CEO Jim Greenwood. “The BIO CEO and Investor Conference will allow investors and companies alike to engage amongst their peers and discover how best to take advantage of the current market opportunities for the year ahead.”
The following companies are slated to present at this year’s conference:
Public Companies:
• Advaxis
• Agenus
• Allergan
• Athersys
• Biodel
• Catalyst Pharmaceutical Partners
• Cempra
• Chimerix*
• Codexis
• CytoDyn
• Epizyme*
• Exelixis
• GENFIT
• GenSpera
• GTx
• Ignyta
• La Jolla Pharmaceutical Company
• Lpath
• NeoStem
• Newron Pharmaceuticals S.p.A.
• Ophthotech*
• OXiGENE
• Prosensa
• pSiVida
• Relypsa*
• Sanofi
• Tekmira Pharmaceuticals Corporation
• Verastem
Private Companies:
• ALS Therapy Development Institute
• Cerecor
• CymaBay
• KineMed
• MaxCyte
• Polynoma
• Trevena
• XDx
*indicates 2013 IPO
Check back often as new presenters are continuously being added. Companies interested in presenting their story can submit an application here.
In addition to Company Presentations, the conference will host Fireside Chats, Therapeutic Workshops, Business Roundtables and the opportunity to arrange meetings between investors, companies and industry executives via BIO’s One-on-One Partnering™ System.
Qualified institutional and venture investors whose primary activity is direct investment in research and development companies are eligible for complimentary registration. Equity research analysts from investment banking institutions also qualify as investors. Media registration also is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.
BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors including supporting banks Leerink Swann and ROTH Capital Partners, LLC.
Upcoming BIO Events
BIO CEO & Investor Conference
February 10 – 11, 2014
New York, NY
BIO Asia International Conference
April 8-9, 2014
Tokyo, Japan
World Congress on Industrial Biotechnology
May 12-15, 2014
Philadelphia, PA
BIO International Convention
June 23-26, 2014
San Diego, CA
Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD
###